glyceryl trioleate
PreclinicalSmall molecule
glyceryl trioleate is one of 9 small molecule programs targeting Adrenoleukodystrophy. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Adrenoleukodystrophy
#DrugCompanyPhaseTrials
1Mirapex
Boehringer IngelheimApproved
Busulfex
Akero TherapeuticsApproved
Cytoxan
BBaxter Healthcare Corporation
Approved
Thalomid
Bristol-Myers SquibbPreclinical
Mesenchymal Stem Cells
JJiangsu Topcel-KH Pharmaceutical Co., Ltd.
Phase 1
Sobetirome
NNeuroVia, Inc.
Phase 2
Interferon-Beta
BiogenPreclinical
Lorenzo's Oil
UUniversity of Minnesota
Preclinical
glyceryl trioleate
FFDA Office of Orphan Products Development
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for glyceryl trioleate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details